Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

NCT01868022 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: GSK3052230
DRUG: paclitaxel
DRUG: carboplatin
DRUG: docetaxel
DRUG: pemetrexed
DRUG: cisplatin

Sponsor

GlaxoSmithKline